CLINICAL TRIALS PROFILE FOR EXJADE
✉ Email this page to a colleague
All Clinical Trials for EXJADE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00171301 ↗ | Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) | Completed | Novartis Pharmaceuticals | Phase 4 | 2005-06-01 | To allow patients treated with deferasirox in the core study to continue iron chelation therapy for 2 years or until the drug became locally commercially available. To evaluate the long-term safety and efficacy of deferasirox by measuring treatment success, change in liver iron content (LIC) and change in serum ferritin levels. Safety was mainly assessed by incidence of adverse events (AEs)and clinically significant lab parameters. |
NCT00235391 ↗ | Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload | Completed | Novartis Pharmaceuticals | Phase 3 | 2005-10-01 | This is an open-label, non-randomized, multi-center trial designed to provide expanded access of deferasirox to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with locally approved iron chelators. |
NCT00419770 ↗ | The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study | Completed | Astellas Pharma Inc | Phase 2 | 2007-10-01 | The purpose of this study is to determine if the addition of the medication, deferasirox, to standard antifungal therapy for the infection, mucormycosis, is safe and effective |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for EXJADE
Condition Name
Clinical Trial Locations for EXJADE
Trials by Country
Clinical Trial Progress for EXJADE
Clinical Trial Phase
Clinical Trial Sponsors for EXJADE
Sponsor Name